CDTX News and Press, Cidara Therapeutics Inc. From 03/31/22

Cidara Therapeutics (NASDAQ:CDTX) dosed the first cohort of healthy volunteers in a phase 1 trial of its antiviral immunotherapy CD388 for preventing seasonal and pandemic influenza. The study is being conducted under an exclusive worldwide license and collaboration agreement with Johnso...

CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention Trial is advancing to dosing subsequent cohorts Initial safety and pharmacokinetics data from study expec...

Cidara Therapeutics press release (NASDAQ:CDTX): Q4 GAAP EPS of -$0.26. Revenue of $7.2M (+94.6% Y/Y). For further details see: Cidara Therapeutics GAAP EPS of -$0.26, revenue of $7.2M

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full y...

Mundipharma and Cidara Therapeutics (NASDAQ:CDTX) said that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. granted rezafungin Promising Innovative Medicine (PIM) designation to treat invasive candidiasis. Invasive candidiasis is an infection caused by a yeast ...

For Trade and Medical Media Only Rezafungin is a next-generation once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia. Despite currently available treatments, the mortality rate...

Cidara Therapeutics (NASDAQ:CDTX) is trading ~3% higher in the pre-market on Monday after the company announced that the FDA accepted its Investigational New Drug (IND) application for the lead flu drug-Fc conjugate (DFC), CD388. Designed based on the company’s Cloudbreak platform, CD3...

Cidara intends to initiate the Phase 1 trial in Q1 2022 Drug-Fc conjugate (DFC) CD388 leverages Cidara’s Cloudbreak® platform and has the potential to offer significant advantages over current flu vaccines in a single seasonal dose SAN DIEGO, Feb. 14, 2022 (GLO...

Gemini Therapeutics (NASDAQ:GMTX) +34%. Galera Therapeutics (NASDAQ:GRTX) +25% raised to Buy at HC Wainwright, BTIG after avasopasem trial met primary endpoint. CMC Materials (NASDAQ:CCMP) +24% Entegris to acquire CMC Materials in a cash and stock transaction worth $6.5B. ...

The decline in Cidara Therapeutics (CDTX -31.0%) that began premarket following the release of top-line data on its phase 3 antifungal candidate rezafungin has continued to widen. Shares are dropping even though the trial met FDA and EMA pre-specified primary endpoints. Earlier this...